Bodal Chemicals has seen an 80% stock surge in four months amid a broad earnings turnaround, driven by diversification, new production at Saykha, and improved balance-sheet management.
Bodal Chemicals has staged a sharp recovery this year, with its latest quarter showing that a long-running chemicals business can still find new momentum through product diversification and tighter balance-sheet control. According to Trade Brains, the stock has risen about 80% in the past four months, reflecting growing investor interest in a turnaround that now rests not only on improved earnings but also on a newly commercialised downstream business.
The company’s June quarter numbers pointed to a broad improvement in operating performance. Trade Brains said revenue climbed 56.1% year on year to ₹715.2 crore, helped by stronger realisations, higher volumes across divisions and the effect of firmer crude-linked input costs. EBITDA rose 45.4% to ₹75.1 crore, although margins eased to 10.5% from 11.3% as raw-material inflation moved faster than top-line gains. LiveMint separately noted that on a sequential basis, total income was ₹454.2 crore and consolidated net profit was ₹9.53 crore, while the company also posted a sharp increase in profit from the previous quarter.
The real surprise came further down the income statement. Trade Brains reported that profit after tax jumped 218.7% to ₹30.4 crore and earnings per share rose to ₹2.4, compared with ₹0.8 a year earlier. The improvement was broad-based across the portfolio: dye intermediates revenue rose 44% to ₹216.6 crore, dyestuff sales gained 23% to ₹149 crore and basic chemicals surged 89% to ₹83.9 crore, while chlor-alkali was up 3% to ₹87 crore. That mix suggests the rebound was not driven by a single product line, but by better pricing and demand across several parts of the business.
A key part of the story is Bodal’s Saykha facility in Gujarat, where commercial production of monochlorobenzene began in December 2023 and output of products such as para-nitrochlorobenzene and ortho-nitrochlorobenzene followed in March 2024, according to Indian Chemical News and Chemical Weekly. Both publications said the plant has 63,000 metric tonnes a year of capacity and could eventually contribute about ₹320 crore in turnover at 12% to 15% margins when fully utilised. Trade Brains said the new benzene derivative line has now begun appearing in the income statement, with management expecting a quarter-on-quarter build-up. The broader company remains highly integrated, with about 40% of basic chemicals consumed internally by the dye intermediates business and around 40% of dye intermediates feeding dyestuffs, a structure that gives Bodal some insulation on costs.
The improvement has also extended to the balance sheet. Trade Brains said net debt-to-equity fell to 0.67 times in FY26 from 0.79 times a year earlier, while working-capital days improved to 104.8 from 124.9. Return on capital employed rose to 8.9% and return on equity to 4.1%, still below the levels the company achieved in stronger years but better than the recent trough. Whether the rally can continue will depend largely on two factors: the pace at which the Saykha business scales and the company’s ability to pass through input-cost swings without sacrificing margins.
Disclaimer: This article is intended to inform and educate, not to recommend or endorse any financial product, investment or strategy. Please consider your own financial circumstances and seek professional advice where appropriate before making financial decisions.
